Lawyers fear Democrats' surge to the White House

Share this article:

Food and drug lawyers at a Washington media briefing in January contended that with Democrats controlling Congress and potentially taking the White House this year, drug companies' worst fears about federal and state legislation regulating drug promotion will become reality. They spoke at Washington Legal Foundation session titled Health Product Promotion: Will New Rules, Greater Disclosure Chill Education and Free Speech?

All three speakers expressed concern that too much attention and resources are being devoted to regulating drug promotion when there is little evidence that prescribers are improperly influenced by promo activities. Marc Scheineson (Alston & Bird) said the perceived high cost of drugs is responsible for much of the attack on drug promotion. “No direct connection has been found between marketing costs and drug costs,” he declared. “If drug companies voluntarily lowered drug prices, all this interest in promotion would disappear.”

Scheineson said the industry is one of the most heavily regulated industries. He said evidence is lacking that docs prescribe drugs based on their relationships with drug companies. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?